RnR Market Research Offers “PharmaSphere: Global Generics Strategy – Key Drivers,Markets and Trends in 2013” Report at US$...
Scope- The report identifies the key generic players in various markets, including a special focus on emergingmarkets such...
6.2.3 Key Players 636.2.4 Australias Healthcare Reform and Impact on the Role of Generics 646.3 Japan 676.3.1 The Japanese...
9.1 Patent expiries and evolution of the regulatory landscape fuel generics 1219.1.1 US patent expiry wave presents a uniq...
Upcoming SlideShare
Loading in …5
×

Global PharmaSphere Generics Strategy Key Drivers, Markets and Trends in 2013

243 views

Published on

“PharmaSphere: Global Generics Strategy – Key Drivers, Markets and Trends in 2013″ report, provides strategic analysis of the global generics industry. It discusses key trends, significant M&A deals in 2012, and describes the operations strategy of these companies.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
243
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global PharmaSphere Generics Strategy Key Drivers, Markets and Trends in 2013

  1. 1. RnR Market Research Offers “PharmaSphere: Global Generics Strategy – Key Drivers,Markets and Trends in 2013” Report at US$ 2995. The report got published in Mar 2013 &Contains 141 Pages.Multinationals Threatening Domestic Growth of India’s Generics Firms, Says GlobalData ReportPreviously considered a thorn in the side of Big Pharma, the Indian generics industry is emerging as akey hunting ground for Multinational Corporations (MNCs) looking to extend their reach into emergingeconomies. Domestic players, however, may pay the price for the intrusion, states the latest report fromresearch and consulting firm GlobalData.The new report* – the first in the company’s new PharmaSphere series – explains that while the Indiangenerics industry has witnessed significant growth over the last year, pharmaceutical giants, which arekeen to leverage the nation’s relatively low cost of production and high quality facilities, may slow thegrowth of India’s domestic companies.Adefemi Adenuga, analyst with GlobalData’s Industry Dynamics Team, says: “Indian generics companies,particularly the smaller ones, do not possess the capabilities to match those of these larger players, andare therefore not able to enjoy the resultant scope and scale economies, which are two key requirementsin the price-sensitive generics business.”Indeed, MNCs are actively positioning themselves to capture a significant portion of the Indian genericsmarket, primarily through authorized generic versions of their off-patent blockbusters. Adenuga states:“The branded generics offered by these large companies may appeal more to the brand-sensitive portionof the Indian population, which now numbers over 1.2 billion, especially if these products are sold atprices that compete well with unbranded pharmaceuticals.”Get Complete Report Details @ http://www.rnrmarketresearch.com/pharmasphere-global-generics-strategy-key-drivers-markets-and-trends-in-2013-market-report.htmlThe GlobalData analyst also believes that the future of the Indian generics market will be shaped by howits government reacts to the current pressure by MNCs regarding the nation’s patent laws. Both Bayerand Novartis have launched strong challenges against India’s compulsory licensing of key drugs over thelast 12 months.“Although the government is currently standing its ground, increasing pressure from Big Pharma mayforce it to relax some of its more stringent laws to favor foreign companies, considering the economicimplications of their presence in the country.“This will come as a blow to domestic generics manufacturers, who often reap the benefits of compulsorylicenses and legal rulings against foreign multinationals.”PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013 report providesstrategic analysis of the global generics industry and discusses key trends, significant M&A deals in 2012,and describes the operations strategy of these companies.This report was built using data and information sourced from proprietary databases, primary andsecondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
  2. 2. Scope- The report identifies the key generic players in various markets, including a special focus on emergingmarkets such as India, China, Russia, and Brazil.- Furthermore, it provides detailed analysis of the various generic markets including the US, Europe,APAC, and BRIC.- The report contains expert insights on the corporate strategies of generic companies seekingcompetitive advantage in the highly competitive generics industry.Reasons to buy- Identify the key generic players in various markets, including the emerging markets such as India,China, Russia, and Brazil- Analyze and track the strategies that successful generic companies are using to gain share in theincreasingly competitive market- Understand the key drivers and trends in the global generics industry- Use this information as an independent source for your due diligence and transaction strategyBuy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=88919Table of Content1 Table of Contents 51.1 List of Tables 91.2 List of Figures 92 Introduction 112.1 Report Scope 112.2 Upcoming Related Reports 122.3 Recently Published Reports 133 Generics Industry Dynamics 143.1 Generics to the Fore 143.1.1 Imminence of the Patent Cliff 143.1.2 Rising healthcare expenditures prompts many governments to resort to generics to save costs 193.1.3 Focus on emerging markets 203.1.4 Generic companies continuously drill holes in Big Pharmas deep pockets 214 Strategic Deals Trends 244.1 Big Pharmas need to plug its revenue gap 264.2 Governments cut healthcare spending as financial austerity spreads globally 264.3 Low margins in the generics business necessitate scale economies 264.4 Highlighted Deals from 2012 274.4.1 Watson Closes $5.5 billion Purchase of Actavis 284.4.2 Mylan Enters into Generics Partnership with Pfizer 314.4.3 Merck and Supera Farma Laboratórios 355 Generics in North America 375.1 Overview 375.2 United States 385.2.1 The US Pharmaceutical Industry 385.2.2 Key Players 505.2.3 Outlook 516 Generics in the Asia-Pacific (APAC) 526.1 Overview 526.2 Australia: Healthcare Policy Reform and the Generics Business 536.2.1 Prescription Drug Regulation and Pricing in Australia 536.2.2 The Australian Generics Business Environment 58
  3. 3. 6.2.3 Key Players 636.2.4 Australias Healthcare Reform and Impact on the Role of Generics 646.3 Japan 676.3.1 The Japanese Pharmaceutical Market 676.3.2 Perception of Generics in Japan 696.3.3 Impact of Pharmacies on Generics Substitution 706.3.4 Generics Approval and Market Exclusivity 716.3.5 Key Players 727 Generics in Europe and Africa 747.1 Overview 747.2 Europe 757.2.1 The Increasing Burden on Healthcare 757.2.2 Case Study: Germany 777.3 Africa 817.3.1 The Need for Local Production 817.3.2 Low regulatory compliance and infrastructure result in a weak pharmaceutical industry 827.3.3 Low standard of living makes medicines unaffordable, discouraging local players 827.3.4 Global organizations and multinationals are standardizing Africas pharmaceutical space 837.3.5 Pharmaceutical Manufacturing Plan for Africa 847.3.6 Case Study: South Africa 848 Generics in the BRIC Countries 948.1 Overview 948.2 Brazil 958.2.1 Latin America Market Leader 958.2.2 Government industrial policies will aid further development of the pharmaceutical industry 968.2.3 Generics in Brazil 978.2.4 Key Players 998.3 Russia 1018.3.1 The New Federal Law on Health in the Russian Federation 1018.3.2 Pharma 2020 will further encourage domestic production in Russia 1038.3.3 Healthy financial situation places less pressure on the Russian government to reduce healthcarecosts 1038.3.4 Key Player 1048.4 India 1058.4.1 Absence of product patents before 2005 triggered the birth of the Indian generics market 1058.4.2 Quality manufacturing facilities create an ideal environment for generics to thrive 1068.4.3 Inter-firm competition enables capabilities development 1078.4.4 Policies and initiatives encourage participation in generics manufacturing by driving demand 1078.4.5 Increased competition from larger multinationals may stymie the development of smaller domesticplayers 1088.4.6 Growing pressures on patent laws could challenge domestic generics manufacturers 1098.4.7 Key Market Players 1108.4.8 Outlook 1138.5 China 1158.5.1 Parallel demographics presents different scenarios on Chinas pharmaceutical industry 1158.5.2 A dysfunctional healthcare system provides little incentive for generics substitution 1168.5.3 Soaring healthcare expenditures pressure Chinas financial stability 1178.5.4 Healthcare reform will level the pharmaceutical industry playing field and foster the growth of thegenerics sector 1188.5.5 Key Players 1198.5.6 Market Outlook 1209 Strategic Outlook 121
  4. 4. 9.1 Patent expiries and evolution of the regulatory landscape fuel generics 1219.1.1 US patent expiry wave presents a unique opportunity for generic manufacturers 1219.1.2 Government reforms will continue to facilitate generic prescribing 1229.1.3 Consolidation sweeps through the generics sector 1229.1.4 Indias generic companies are an emerging force in the global generics market 12310 Appendix 12410.1 Bibliography 12410.2 Abbreviations 13210.3 Research Methodology 13710.3.1 Coverage 13710.3.2 Secondary Research 13810.3.3 Expert Panel Validation 13810.4 About the Authors 13810.4.1 Analyst 13810.4.2 Director of Healthcare Industry Dynamics 13910.4.3 Global Head of Healthcare Research and Consulting 13910.5 About the Industry Dynamics Team 14010.6 About GlobalData 14010.7 Contact Us 14110.8 Disclosure Information 14110.9 Disclaimer 141For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com/

×